Description:

Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT01688700

Link:

https://clinicaltrials.gov/show/NCT01688700

Keywords:
Versions (1) ▾
  1. 12/16/19
Copyright Holder:
See clinicaltrials.gov
Uploaded on:

December 16, 2019

DOI:
No DOI assigned. To request one please log in.
License:
Creative Commons BY 4.0
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Esophageal Squamous Cell Carcinoma Resectable NCT01688700

Details

Eligibility Esophageal Squamous Cell Carcinoma Resectable NCT01688700

Inclusion Criteria
histological or cytologic diagnosis of esophageal squamous cell carcinoma
ecog performance status 0-2
age:18-70 years
joined the study voluntarily and signed informed consent form
patients must not have received any prior anticancer therapy
resectable disease, stage iia-iiic, t2n0m0-t3n1m0（ajcc 2009）
target lesions can be measured according to recist criteria
no serious system dysfunction and immuno-deficiency, adequate organ function including the following: hemoglobin ≥9 g/dl, wbc≥3x109/l, neutrophils (anc )≥1.5x109/l, platelet count ≥100x 109/l, tbil<1.5 x uln, alt and ast ≦ 2.5 x uln, creatinine ≦ 1.5 x uln
use of an effective contraceptive for adults to prevent pregnancy
life expectancy of more than 3 months
Exclusion Criteria
not suitable to surgery
cervical esophageal carcinoma(distance of incisor tooth<19cm)
early esophageal carcinoma(stage i)
complete esophageal obstruction，esophageal perforation or hematemesis
other malignant tumors, except for skin basal cell carcinoma, or cervical carcinoma in situ
pregnant or breast-feeding women or people during the birth-period who refused to take contraceptives
uncontrolled seizures or psychiatric diseases, loss of control over their own behavior 11、 history of serious allergic or castor oil allergy 12、 patients who are not suitable to participate in the trial according to researchers
Back to the top of the page